Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE-HF: Bisoprolol N-of-1 in Heart Failure
NCT07029906Recruiting
- Sponsor
- Imperial College London
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of bisoprolol in heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by Imperial College London. Primary endpoint: Nocebo Fraction at 15 weeks. Started Apr 2025; status: recruiting.
02
Drugs
bisoprolol
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07029906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029906.